Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02860780 · ClinicalTrials.gov registry record · Phase 1
A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02860780 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 9 participants.
The verdict
NCT02860780, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety of the study drug prexasertib in combination with ralimetinib in participants with advanced or metastatic cancer.
Interventions
- DRUG prexasertib
- DRUG ralimetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-08-10 |
| Est. Completion | 2017-05-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02860780
The ClinicalTrials.gov registry entry for NCT02860780 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which prexasertib is the first listed.
NCT02860780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02860780 about?
NCT02860780 is a clinical study titled "A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer". The main purpose of this study is to evaluate the safety of the study drug prexasertib in combination with ralimetinib in participants with advanced or metastatic cancer.
What is the current status of trial NCT02860780?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2016-08-10. Estimated completion is 2017-05-15.
What interventions are being tested in trial NCT02860780?
The interventions under investigation include: prexasertib (DRUG), ralimetinib (DRUG).
Who is sponsoring clinical trial NCT02860780?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.